Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

2760 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-17

Study Completion Date

2035-12-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine whether long-term treatment with oral betablocker therapy after myocardial infarction in patient with no heart failure reduces the composite outcome of recurrent MI, all-cause mortality, revascularisation with percutaneous coronary intervention or coronary artery bypass graft, ischemic stroke, incident heart failure, or malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy

NCT05569382

Non-obstructive Hypertrophic Cardiomyopathy

RECRUITING PHASE4

Beta 3 Agonist Treatment in Heart Failure-2

NCT03926754

Heart Failure With Reduced Ejection Fraction NYHA Class III-IV

COMPLETED PHASE2/PHASE3

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction

NCT05350969

Myocardial Infarction, Acute Heart Failure, Left Sided

COMPLETED PHASE2

RESynchronizaTiOn theRapy and bEta-blocker Titration

NCT02173028

Beta Blocker Intolerance Congestive Heart Failure

COMPLETED

Beta-Blocker Heart Attack Trial (BHAT)

NCT00000492

Arrhythmia Cardiovascular Diseases Coronary Disease +5 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aim: To determine whether long-term treatment with oral betablocker (BB) therapy after myocardial infarction (MI) in patient with no heart failure reduces the composite outcome of recurrent MI, all-cause mortality, revascularisation with percutaneous coronary intervention or coronary artery bypass graft, ischemic stroke, incident heart failure, or malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin.

The inclusion- and event rate in DANBLOCK have been continuously assessed since the first patient was randomized in December 2018. The inclusion- and event rate have been lower than expected, in part due to COVID-19. To enhance feasibility, the decision was made by the Steering Committees to combine the data from DANBLOCK with the data from the Norwegian BETAMI (NCT03646357) and publish the primary endpoint, key secondary endpoints and most other secondary endpoints together (presented below).

The trials have similar designs, only minor differences in study entry criteria, and were, from the very beginning, coordinated with the aim of conducting sub-studies on pooled data. The primary endpoint has been harmonized without knowledge of the distribution of events. BETAMI and DANBLOCK will remain separate trials until the end of follow-up, where data from the trials will be combined and main results published together.

Intervention: BB therapy versus no therapy.

Main Inclusion Criteria: Patient that have suffered a MI, both Non-ST elevation MI and ST elevation MI and can be randomized within 14 days of MI with no signs of heart failure and a left ventricular ejection fraction\>40%.

Main Exclusion Criteria: Any indication or contraindication for BB treatment other than secondary prevention according to the treating cardiologist

Primary study endpoint:

• The composite of all-cause mortality, recurrent MI, revascularisation with PCI or CABG, ischemic stroke, incident heart failure, or malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin.

Key secondary endpoints to be included in the main publication:

* Each of the components of the primary endpoint, i.e.: All-cause mortality, recurrent MI, revascularisation with PCI or CABG, ischemic stroke, incident heart failure, malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin.
* To study whether oral beta-blocker therapy increases the risk of hospitalization for 2 or 3rd degree AV-block, or implantation of pacemaker
* To assess clinical outcomes linked to beta-blocker therapy in the following subgroups:

age (\> vs \<70 years), sex (men vs. women), beta-blocker dosage, STEMI vs. NSTEMI, LVEF subgroups (preserved vs. mid-range), country, hypertension and diabetes.

Other secondary endpoints are described in the Statistical Analysis Plan and under "Outcome Measures".

Other secondary objectives (for BETAMI-DANBLOCK substudies unless specified otherwise):

* To study whether oral beta-blocker therapy reduces the risk of cardiovascular death compared to no such therapy
* To study whether oral beta-blocker therapy reduces the risk of stable and unstable angina compared to no such therapy
* To study whether oral beta-blocker therapy reduces the risk of atrial fibrillation, atrial flutter or other tachyarrhythmias compared to no such therapy
* To study whether oral beta-blocker therapy increases the risk of hospitalization for chronic obstructive pulmonary disease, asthma or peripheral artery disease.
* To study whether oral beta-blocker therapy increases the risk of hospitalization or outpatient visit for new-onset or dysregulated diabetes (DANBLOCK only)
* To study whether oral beta-blocker therapy affects the following patient related outcomes: Quality of life, angina, dyspnoea, anxiety, depression, sexual dysfunction or sleep disorders.
* To conduct cost-utility analysis in relation to quality of life and a health economic evaluation including drug use, health care utilization, employment, income, and benefit take-up
* To describe beta-blocker dosage and adherence
* To assess study safety

Safety endpoints:

The following safety endpoints will be reported in the main publication:

* Primary safety endpoint: A composite of all-cause mortality, recurrent MI, incident HF, malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin at 30 days following randomization
* Other safety endpoint: All-Cause Mortality: A table of all deaths within the follow-up period
* Other safety endpoint: Suspected Unexpected Serious Adverse Reaction (SUSARs): A table of all SUSARs within the follow-up period with number and frequency in each group. Reported by local investigators and obtained from the study databases.

All serious adverse events, including potential endpoints, are captured in the study database to be used for safety assessments and are reported continuously to regulatory authorities.

Sample Size: A total of approximately 2760 patients will be recruited and randomized 1:1 to BB treatment (type and dosage according to treating physician) or no BB treatment. Treatment must be initiated within 14 days of MI.

Sample size considerations: The study is event driven and a power calculation for the combined DANBLOCK-BETAMI trial has been performed in which 950 events will provide a power of 80% to detect a true treatment effect equal to a hazard ratio of 1.2 for no beta-blocker therapy.

Location: All departments of cardiology in Denmark are invited to participate. All patients admitted to hospital for MI will be screened for in- and exclusion criteria and contacted if eligible.

Treatment Duration: Estimated (non) treatment duration of a minimum of 6 months and a maximum of 6.25 years (anticipated).

Follow-up: Patients will be followed from the randomization date until end of follow-up.

Intervention and dosage of BB treatment: The intervention will be active treatment with BB, type and dosage according to treating cardiologist choice and control will be standard care (without BB treatment). The treating cardiologist is recommended to use the highest dose deemed tolerable for the patient at the time of randomization. Dosage, adherence and cross-over will be monitored through linkage to the Danish Register of Medical Product Statistics.

Original sample size considerations: Assuming a hazard ratio of 1.2 for the non-treated group compared to the treated the DANBLOCK trial has 80% power to detect this effect with an accumulation of 900 events of the primary endpoint. With approximately 3570 patients randomized the investigators expect to reach 900 events within the study period.

Statistical Analysis: Please see the Statistical Analysis Plan.

Data Safety Monitoring Board (DSMB): This committee consisting of two senior cardiologists and one trial-science statistician will overview safety and will have access to unblinded data. They will formally review the accumulating data every 6 months throughout the study period to ensure there is no avoidable increased harm to patients. The DSMB may recommend trial termination due to excess risk associated with no treatment with BB.

Recruitment: All patients admitted to hospital for MI will be screened for in- and exclusion criteria and contacted if eligible. Logistics of identifying and contacting the patients will be organized locally; some hospitals will randomize patients before discharge, others will contact patients after discharge. Patients will be randomized 1:1.

Publication policy: On study completion the results will be submitted for publication in an international medical journal. The results of this study will also be submitted to the Competent Authority and the Ethics Committee according to EU and Danish regulations.

Furthermore, a joint analysis of the data from BETAMI-DANBLOCK with the REDUCE (NCT03278509), CAPITAL-RCT (NCT01155635), and REBOOT (NCT03596385) trials will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Myocardial Infarction Non-ST Elevation Myocardial Infarction (nSTEMI) ST Elevation Myocardial Infarction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective, randomized, controlled, open-label, blinded endpoint (PROBE design)

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Beta blocker treatment

Treatment with beta blockers plus standard of care. Type and dosage according to treating cardiologist choice

* Bisoprolol up to a total dose of 10 mg daily
* Carvedilol up to a total dose of 50 mg daily
* Metoprolol succinate up to a total dose of 200 mg daily
* Nebivolol up to a total dose of 10 mg daily

Group Type EXPERIMENTAL

Metoprolol Succinate

Intervention Type DRUG

Eligible patients randomized to receive long-term therapy with oral beta-blockade

Bisoprolol

Intervention Type DRUG

Eligible patients randomized to receive long-term therapy with oral beta-blockade

Carvedilol

Intervention Type DRUG

Eligible patients randomized to receive long-term therapy with oral beta-blockade

Nebivolol

Intervention Type DRUG

Eligible patients randomized to receive long-term therapy with oral beta-blockade

No beta blocker treatment

Standard care without beta blocker treatment

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metoprolol Succinate

Eligible patients randomized to receive long-term therapy with oral beta-blockade

Intervention Type DRUG

Bisoprolol

Eligible patients randomized to receive long-term therapy with oral beta-blockade

Intervention Type DRUG

Carvedilol

Eligible patients randomized to receive long-term therapy with oral beta-blockade

Intervention Type DRUG

Nebivolol

Eligible patients randomized to receive long-term therapy with oral beta-blockade

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Left ventricular ejection fraction \> 40%
* Myocardial infarction (MI) within previous two weeks

The diagnosis of acute MI must meet the Universal European Society of Cardiology (ESC) definition of MI

Exclusion Criteria

* Clinical evidence of heart failure at the time of discharge
* Pregnancy or of child bearing age not using safe anticonception throughout the study period
* Lack of signed informed consent and expected cooperation during follow-up
* Any medical condition where beta blocker treatment is indicated according to the treating physician

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No